Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial

Risankizumab, a humanized immunoglobulin G1 monoclonal antibody, selectively inhibits interleukin‐23, a key cytokine in the pathogenesis of psoriasis, by binding to its p19 subunit. In SustaIMM (ClinicalTrials.gov/NCT03000075), a phase 2/3, double‐blinded, placebo‐controlled study, Japanese patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohtsuki, Mamitaro, Fujita, Hideki, Watanabe, Mitsunori, Suzaki, Keiko, Flack, Mary, Huang, Xin, Kitamura, Susumu, Valdes, Joaquin, Igarashi, Atsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771602/
https://www.ncbi.nlm.nih.gov/pubmed/31237727
http://dx.doi.org/10.1111/1346-8138.14941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771602/
https://www.ncbi.nlm.nih.gov/pubmed/31237727
http://dx.doi.org/10.1111/1346-8138.14941

Ejemplares similares